Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Core Viewpoint - Evaxion A/S has lost the option for its Gonorrhea vaccine candidate EVX-B2 from MSD, but retains global rights and will seek another licensing partner while remaining committed to the program [1][4][8] Group 1: Company Developments - MSD will not exercise its option for the EVX-B2 vaccine candidate, allowing Evaxion to pursue other licensing opportunities [1][8] - Earlier in the year, MSD exercised its option for another Evaxion vaccine candidate, EVX-B3, which could yield milestone payments up to $592 million and royalties on net sales [2] - Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics [5] Group 2: Vaccine Candidate Insights - Gonorrhea affects over 80 million people globally each year, and no vaccine has been approved to date despite extensive research [3] - Preclinical studies indicate that EVX-B2 provides protection against Gonorrhea bacteria, showcasing the potential of Evaxion's AI-Immunology™ platform [3][4] - The company remains optimistic about EVX-B2's potential to be the first approved vaccine for Gonorrhea, addressing a significant unmet medical need [4][8] Group 3: Financial Outlook - The decision by MSD does not impact Evaxion's cash runway, which is projected to extend into the second half of 2027 [5][8]